The Specialty Generics Market is expected to register a CAGR of 9.1% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the Specialty Generics Market is segmented by product type into injectables, oral solids, and topical formulations. Applications analyzed include oncology, autoimmune disorders, respiratory diseases, cardiovascular diseases, and central nervous system (CNS) disorders. End-users include hospitals, specialty clinics, pharmacies, and pharmaceutical manufacturers. The regional analysis covers key markets such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.
Purpose of the ReportThe report Specialty Generics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Specialty Generics Market Segmentation
Formulation Type- oral
- parenteral
- topical
- Oncology
- Inflammatory Conditions
- Multiple Sclerosis
- Hepatitis C
- Specialty Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
Strategic Insights
Specialty Generics Market Growth Drivers- Increased Demand for Economic Alternatives in Treatment:
As chronic diseases like cancer, multiple sclerosis, autoimmune disorders, and cardiovascular diseases continue to grow, there is an interest in developing cost-effective alternatives to treatment. Specialty generics, which are essentially lower-cost versions of branded specialty drugs, offer significant savings while maintaining efficacy in treatment. Due to rising healthcare costs and strained healthcare budgets, patients and healthcare providers are gradually shifting toward specialty generics as an economical alternative. This demand is higher in markets wherein government regulations place a greater emphasis on cost containment in pharmaceutical spending, such as the U.S. and European countries. - Specialty Drug Patent Expiration: Increased demand in the specialty generics market has arisen as the patents of blockbuster specialty drugs expire. Patent expiries for biologics and specialty pharmaceuticals have given generic manufacturers the opportunity to scale into the market with lower-cost alternatives. This encourages further market penetration with increased access for patients to specialty treatments. The upcoming exclusive drug patent expirations, especially in the oncology, immunology, and neurology fields, would promote the growth of specialty generics, thus opening up lucrative avenues for pharmaceutical companies to enter this high-value market segment.
- Rising Incidence of Complex and Rare Diseases: Complex and rare diseases have, in turn, increased the demand for specialty medications, which are in many cases expensive because of the targeted mechanisms and advanced formulations. Specialty generics offer an affordable option for conditions such as multiple sclerosis, rheumatoid arthritis, and rare cancers, which require long-term treatment. With the improved awareness and diagnosis of rare diseases, the demand for specialty generics is anticipated to gain momentum, enabling patients to receive vital medications at lower investments. This factor is especially pertinent in emerging markets, where high drug costs can restrict treatment options.
- Accelerated Adoption of Biosimilars: Biosimilars are essentially specialty generics, which have recorded rapid growth in use because of their cost advantage over biologic drugs. Favorable developments in the regulatory environment that support biosimilars have led to extensive investments by pharmaceutical companies in developing biosimilar versions of some high-cost biological therapies. Areas such as oncology and autoimmune diseases exhibit particularly rapid growth of biosimilars, on the back of growing confidence by physicians and patients alike in the drugs. Biosimilars are key in boosting the franchise of specialty generics over the foreseeable future.
- Regulatory Support for Generic Approvals: Regulatory agencies such as the FDA and EMA are working to promote the development and approval of specialty generics to promote competition and lower drug prices. Enhancing the approval pathway for consideration along with generic manufacturer incentives and addressing other regulatory bottlenecks will spur market expansion. The introduction of policies such as CGT is expected to speed up the approval process of specialty generics, allowing them to gain market recognition faster.
- Expansion of Specialty Pharmacy Services: The rise of specialty pharmacies is greatly influencing distribution and access to specialty generics. Specialty pharmacies focus on the provision of complex, high-cost medications and enhance patient adherence, education, and monitoring. As healthcare systems increasingly depend on specialty pharmacies for the treatment of chronic and rare diseases, specialty generic manufacturers equip themselves with specialty pharmacies to ensure their products reach various markets. Such a trend is already evident in developed markets such as the U.S. The U.S. specialty pharmacy market plays a major role in the market access of specialty medications.
- Development of Complex Injectable and Transdermal Specialty Generics: The specialty generics market is moving beyond traditional oral formulations toward more complex drug delivery systems, including injectables, transdermal patches, and inhalers. These dosage forms require specialized manufacturing capabilities and regulatory approvals, creating a high-entry barrier for competitors. Companies that invest in developing complex specialty generics can gain a strong foothold in this market, particularly for chronic conditions requiring long-term medication, such as diabetes, neurological disorders, and cancer.
- Increasing Collaborations Between Generic Manufacturers and Biopharma Companies: Strategic collaborations and partnerships between generic drug manufacturers and biotechnology or pharmaceutical companies are creating new growth avenues in the specialty generics market. These partnerships allow generic manufacturers to access advanced R&D capabilities, improve manufacturing processes, and accelerate regulatory approvals. Licensing agreements, joint ventures, and co-development initiatives are becoming increasingly common as companies seek to capitalize on the growing demand for specialty generics while leveraging the expertise of established biopharma firms.
- Rising Demand for Specialty Generics in Oncology and Autoimmune Diseases: Oncology and autoimmune disease segments are among the fastest-growing ones in the specialty generics market. With the growing prevalence of lung, breast, and colorectal cancers worldwide, the need for affordable chemotherapy and targeted continuation drugs increases. Likewise, the autoimmune diseases-rheumatoid arthritis, lupus, and multiple sclerosis-are long-therapeutic conditions requiring high-cost medications. Specialty generic drugs in these therapeutic areas are noteworthy candidates for cost-savings and can serve as critical drugs for many patients. The focus on developing generics for oncology and autoimmune characteristics presents an opportunity for uncovering developing markets.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Specialty Generics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Specialty Generics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Specialty Generics Market is expected to register a CAGR of 9.1% from 2025-2031.
The major driving factors supporting the Specialty Generics Market growth are- Increased Demand for Economic Alternatives in Treatment and Specialty Drug Patent Expiration
Key Future Trends in the Specialty Generics Market are- Accelerated Adoption of Biosimilars, Regulatory Support for Generic Approvals, and Expansion of Specialty Pharmacy Services
Key companies in the Specialty Generics Market are - Valeant Pharmaceuticals International, Inc., Novartis, Pfizer Inc., Turing Pharmaceuticals, Teva Pharmaceutical Ltd., Mylan N.V., Akorn, Inc., Mallinckrodt, Lupin Pharmaceuticals
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Specialty Generics Market - By Formulation type
1.3.2 Specialty Generics Market - By Therapeutic Application
1.3.3 Specialty Generics Market - By Distributional Channel
1.3.4 Specialty Generics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. SPECIALTY GENERICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. SPECIALTY GENERICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. SPECIALTY GENERICS MARKET - GLOBAL MARKET ANALYSIS
6.1. SPECIALTY GENERICS - GLOBAL MARKET OVERVIEW
6.2. SPECIALTY GENERICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. SPECIALTY GENERICS MARKET - REVENUE AND FORECASTS TO 2028 - FORMULATION TYPE
7.1. OVERVIEW
7.2. FORMULATION TYPE MARKET FORECASTS AND ANALYSIS
7.3. ORAL
7.3.1. Overview
7.3.2. Oral Market Forecast and Analysis
7.4. PARENTERAL
7.4.1. Overview
7.4.2. Parenteral Market Forecast and Analysis
7.5. TOPICAL
7.5.1. Overview
7.5.2. Topical Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. SPECIALTY GENERICS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC APPLICATION
8.1. OVERVIEW
8.2. THERAPEUTIC APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. INFLAMMATORY CONDITION
8.4.1. Overview
8.4.2. Inflammatory condition Market Forecast and Analysis
8.5. MULTIPLE SCLEROSIS
8.5.1. Overview
8.5.2. Multiple sclerosis Market Forecast and Analysis
8.6. HEPATITIS C
8.6.1. Overview
8.6.2. Hepatitis C Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. SPECIALTY GENERICS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTIONAL CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTIONAL CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. SPECIALTY PHARMACY
9.3.1. Overview
9.3.2. Specialty pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail pharmacy Market Forecast and Analysis
9.5. HOSPITAL PHARMACY
9.5.1. Overview
9.5.2. Hospital pharmacy Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. others Market Forecast and Analysis
10. SPECIALTY GENERICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Specialty Generics Market Overview
10.1.2 North America Specialty Generics Market Forecasts and Analysis
10.1.3 North America Specialty Generics Market Forecasts and Analysis - By Formulation type
10.1.4 North America Specialty Generics Market Forecasts and Analysis - By Therapeutic Application
10.1.5 North America Specialty Generics Market Forecasts and Analysis - By Distributional Channel
10.1.6 North America Specialty Generics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Specialty Generics Market
10.1.6.1.1 United States Specialty Generics Market by Formulation type
10.1.6.1.2 United States Specialty Generics Market by Therapeutic Application
10.1.6.1.3 United States Specialty Generics Market by Distributional Channel
10.1.6.2 Canada Specialty Generics Market
10.1.6.2.1 Canada Specialty Generics Market by Formulation type
10.1.6.2.2 Canada Specialty Generics Market by Therapeutic Application
10.1.6.2.3 Canada Specialty Generics Market by Distributional Channel
10.1.6.3 Mexico Specialty Generics Market
10.1.6.3.1 Mexico Specialty Generics Market by Formulation type
10.1.6.3.2 Mexico Specialty Generics Market by Therapeutic Application
10.1.6.3.3 Mexico Specialty Generics Market by Distributional Channel
10.2. EUROPE
10.2.1 Europe Specialty Generics Market Overview
10.2.2 Europe Specialty Generics Market Forecasts and Analysis
10.2.3 Europe Specialty Generics Market Forecasts and Analysis - By Formulation type
10.2.4 Europe Specialty Generics Market Forecasts and Analysis - By Therapeutic Application
10.2.5 Europe Specialty Generics Market Forecasts and Analysis - By Distributional Channel
10.2.6 Europe Specialty Generics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Specialty Generics Market
10.2.6.1.1 Germany Specialty Generics Market by Formulation type
10.2.6.1.2 Germany Specialty Generics Market by Therapeutic Application
10.2.6.1.3 Germany Specialty Generics Market by Distributional Channel
10.2.6.2 France Specialty Generics Market
10.2.6.2.1 France Specialty Generics Market by Formulation type
10.2.6.2.2 France Specialty Generics Market by Therapeutic Application
10.2.6.2.3 France Specialty Generics Market by Distributional Channel
10.2.6.3 Italy Specialty Generics Market
10.2.6.3.1 Italy Specialty Generics Market by Formulation type
10.2.6.3.2 Italy Specialty Generics Market by Therapeutic Application
10.2.6.3.3 Italy Specialty Generics Market by Distributional Channel
10.2.6.4 Spain Specialty Generics Market
10.2.6.4.1 Spain Specialty Generics Market by Formulation type
10.2.6.4.2 Spain Specialty Generics Market by Therapeutic Application
10.2.6.4.3 Spain Specialty Generics Market by Distributional Channel
10.2.6.5 United Kingdom Specialty Generics Market
10.2.6.5.1 United Kingdom Specialty Generics Market by Formulation type
10.2.6.5.2 United Kingdom Specialty Generics Market by Therapeutic Application
10.2.6.5.3 United Kingdom Specialty Generics Market by Distributional Channel
10.2.6.6 Rest of Europe Specialty Generics Market
10.2.6.6.1 Rest of Europe Specialty Generics Market by Formulation type
10.2.6.6.2 Rest of Europe Specialty Generics Market by Therapeutic Application
10.2.6.6.3 Rest of Europe Specialty Generics Market by Distributional Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Specialty Generics Market Overview
10.3.2 Asia-Pacific Specialty Generics Market Forecasts and Analysis
10.3.3 Asia-Pacific Specialty Generics Market Forecasts and Analysis - By Formulation type
10.3.4 Asia-Pacific Specialty Generics Market Forecasts and Analysis - By Therapeutic Application
10.3.5 Asia-Pacific Specialty Generics Market Forecasts and Analysis - By Distributional Channel
10.3.6 Asia-Pacific Specialty Generics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Specialty Generics Market
10.3.6.1.1 Australia Specialty Generics Market by Formulation type
10.3.6.1.2 Australia Specialty Generics Market by Therapeutic Application
10.3.6.1.3 Australia Specialty Generics Market by Distributional Channel
10.3.6.2 China Specialty Generics Market
10.3.6.2.1 China Specialty Generics Market by Formulation type
10.3.6.2.2 China Specialty Generics Market by Therapeutic Application
10.3.6.2.3 China Specialty Generics Market by Distributional Channel
10.3.6.3 India Specialty Generics Market
10.3.6.3.1 India Specialty Generics Market by Formulation type
10.3.6.3.2 India Specialty Generics Market by Therapeutic Application
10.3.6.3.3 India Specialty Generics Market by Distributional Channel
10.3.6.4 Japan Specialty Generics Market
10.3.6.4.1 Japan Specialty Generics Market by Formulation type
10.3.6.4.2 Japan Specialty Generics Market by Therapeutic Application
10.3.6.4.3 Japan Specialty Generics Market by Distributional Channel
10.3.6.5 South Korea Specialty Generics Market
10.3.6.5.1 South Korea Specialty Generics Market by Formulation type
10.3.6.5.2 South Korea Specialty Generics Market by Therapeutic Application
10.3.6.5.3 South Korea Specialty Generics Market by Distributional Channel
10.3.6.6 Rest of Asia-Pacific Specialty Generics Market
10.3.6.6.1 Rest of Asia-Pacific Specialty Generics Market by Formulation type
10.3.6.6.2 Rest of Asia-Pacific Specialty Generics Market by Therapeutic Application
10.3.6.6.3 Rest of Asia-Pacific Specialty Generics Market by Distributional Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Specialty Generics Market Overview
10.4.2 Middle East and Africa Specialty Generics Market Forecasts and Analysis
10.4.3 Middle East and Africa Specialty Generics Market Forecasts and Analysis - By Formulation type
10.4.4 Middle East and Africa Specialty Generics Market Forecasts and Analysis - By Therapeutic Application
10.4.5 Middle East and Africa Specialty Generics Market Forecasts and Analysis - By Distributional Channel
10.4.6 Middle East and Africa Specialty Generics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Specialty Generics Market
10.4.6.1.1 South Africa Specialty Generics Market by Formulation type
10.4.6.1.2 South Africa Specialty Generics Market by Therapeutic Application
10.4.6.1.3 South Africa Specialty Generics Market by Distributional Channel
10.4.6.2 Saudi Arabia Specialty Generics Market
10.4.6.2.1 Saudi Arabia Specialty Generics Market by Formulation type
10.4.6.2.2 Saudi Arabia Specialty Generics Market by Therapeutic Application
10.4.6.2.3 Saudi Arabia Specialty Generics Market by Distributional Channel
10.4.6.3 U.A.E Specialty Generics Market
10.4.6.3.1 U.A.E Specialty Generics Market by Formulation type
10.4.6.3.2 U.A.E Specialty Generics Market by Therapeutic Application
10.4.6.3.3 U.A.E Specialty Generics Market by Distributional Channel
10.4.6.4 Rest of Middle East and Africa Specialty Generics Market
10.4.6.4.1 Rest of Middle East and Africa Specialty Generics Market by Formulation type
10.4.6.4.2 Rest of Middle East and Africa Specialty Generics Market by Therapeutic Application
10.4.6.4.3 Rest of Middle East and Africa Specialty Generics Market by Distributional Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Specialty Generics Market Overview
10.5.2 South and Central America Specialty Generics Market Forecasts and Analysis
10.5.3 South and Central America Specialty Generics Market Forecasts and Analysis - By Formulation type
10.5.4 South and Central America Specialty Generics Market Forecasts and Analysis - By Therapeutic Application
10.5.5 South and Central America Specialty Generics Market Forecasts and Analysis - By Distributional Channel
10.5.6 South and Central America Specialty Generics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Specialty Generics Market
10.5.6.1.1 Brazil Specialty Generics Market by Formulation type
10.5.6.1.2 Brazil Specialty Generics Market by Therapeutic Application
10.5.6.1.3 Brazil Specialty Generics Market by Distributional Channel
10.5.6.2 Argentina Specialty Generics Market
10.5.6.2.1 Argentina Specialty Generics Market by Formulation type
10.5.6.2.2 Argentina Specialty Generics Market by Therapeutic Application
10.5.6.2.3 Argentina Specialty Generics Market by Distributional Channel
10.5.6.3 Rest of South and Central America Specialty Generics Market
10.5.6.3.1 Rest of South and Central America Specialty Generics Market by Formulation type
10.5.6.3.2 Rest of South and Central America Specialty Generics Market by Therapeutic Application
10.5.6.3.3 Rest of South and Central America Specialty Generics Market by Distributional Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL SPECIALTY GENERICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. SPECIALTY GENERICS MARKET, KEY COMPANY PROFILES
13.1. VALEANT PHARMACEUTICALS INTERNATIONAL, INC
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. NOVARTIS
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PFIZER INC
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. TURING PHARMACEUTICALS
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. TEVA PHARMACEUTICAL LTD
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MYLAN NV
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. AKORN, INC
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. MALLINCKRODT
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. LUPIN PHARMACEUTICALS
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. SANDOZ
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERM
1. Valeant Pharmaceuticals International, Inc.,
2. Novartis
3. Pfizer Inc.,
4. Turing Pharmaceuticals,
5. Teva Pharmaceutical Ltd.,
6. Mylan N.V.,
7. Akorn, Inc.,
8. Mallinckrodt
9. Lupin Pharmaceuticals
10. Sandoz
11. Sun Pharmaceuticals
12. Amneal Pharmaceuticals
13. Par Pharmaceuticals
14. Endo Pharmaceuticals
15. Actavis
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For